Document is current
Any future updates will be listed below
-
Authors
Wang, Li
Liu, Jiaying
Zhou, Keshu
Li, Zengjun
Zeng, Yun
Qian, Ying
Sun, Yuping
Wu, Hui
Roerker, Lindsay
Tan, Peter
Ma, Chen
Zhou, Liwei
Duan, Xianlin
Kang, Xiaoyan
Zhao, Weili
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (82570246)
National Natural Science Foundation of China (82530008)
Noncommunicable Chronic Diseases-National Science and Technology Major Project (2026ZD055390)
Shanghai Lymphoma Clinical Cohort of Shanghai Hospital Development Center (SHDC2025CCS008)
Shanghai Clinical Research Center for Cell Therapy (23J41900100)
Collaborative Innovation Center of Systems Biomedicine
- License Information
-
More Information
Article History
Received: 26 December 2025
Accepted: 6 April 2026
First Online: 29 May 2026
Declarations
:
: This study was done in accordance with the principles of the Declaration of Helsinki, the international standards of good clinical practice, and applicable local laws and regulations. The study protocol and all amendments were reviewed and approved by the institutional review board or independent ethics committee at each participating site. All patients provided written informed consent before enrollment.
: Not applicable.
: Li Wang, Jiaying Liu, Keshu Zhou, Zengjun Li, Yun Zeng, Ying Qian, Yuping Sun, Hui Wu, Lindsay Roerker, Peter Tan, and Weili Zhao declare that they have no conflict of interest. Chen Ma, Liwei Zhou, Xianlin Duan, and Xiaoyan Kang are full-time employees of Qilu Pharmaceutical Co., Ltd.
